Moreover, inhibition of FABP4 by its small molecule inhibitor, BMS309403, reduced the tumor burden and highly increased the sensitivity of ovarian cancer cells to carboplatin, both in vitro as well as in vivo [74]. This evidence concerns the gene FABP4 and ovarian carcinoma.